Audience: Clinicians. Published 16 November 2026 (AEDT). ARTG registration 3 November 2026; AusPAR PI attachment dated 11 November 2026.

Oral semaglutide (Wegovy tablet 1.5, 4, 9 and 25 mg) is now registered for chronic weight management in adults (BMI ≥30, or ≥27 with a weight-related comorbidity) and for MACE risk reduction in adults with established CVD, BMI ≥27 and no diabetes. Adolescent and MASH indications remain injection-only.

Evidence

OASIS 4 (NEJM 2025; Novo Nordisk-funded): double-blind RCT, 307 adults without diabetes, randomised 2:1 to oral semaglutide 25 mg daily or placebo plus lifestyle intervention, 64 weeks. Mean baseline BMI 37.6; 91.5% White, 0.7% Asian. Weight change −13.6% vs −2.2% (difference −11.4 points, 95% CI −13.9 to −9.0; treatment-policy estimand). ≥15% loss 47.0% vs 5.4%. GI adverse events 74.0% vs 42.2%. Treatment discontinuation 18% vs 25.5%. Systolic BP difference was not significant. The PI reports exposure comparable to subcutaneous 2.4 mg in STEP 1; MACE data derive from SELECT (injection), not a tablet outcome trial.

Practical points

  • Fasting ≥8 hours, swallow whole with ≤120 mL water, wait ≥30 minutes before food, drink or other oral medicines; the PI notes waiting less than 30 minutes may reduce absorption.
  • Titrate 1.5 → 4 → 9 → 25 mg, at least one month per step; one tablet daily only. Skip missed doses.
  • From 2.4 mg weekly injection, start 25 mg tablet one week after the last injection.
  • Avoid with other GLP-1 RAs. Category D; stop ≥2 months before planned pregnancy. Contraindicated with personal or family history of MTC or MEN 2.
  • Not yet marketed at the time of writing; not PBS-subsidised for weight management.

Limitations

Single moderate-sized trial (22 sites, four countries), limited ethnic diversity, no participants with diabetes, and no head-to-head comparison with injectable semaglutide or tirzepatide. Full NEJM text was not reviewed; figures were checked against the TGA PI.

Prepared with AI assistance from the linked sources; not individually reviewed by a clinician. General information only, not individual medical advice.

Sources

TGA: Australian Product Information for Wegovy (semaglutide), AusPAR attachment dated 11 November 2026 (accessed 16 November 2026, AEDT).
Wharton S, et al. OASIS 4. N Engl J Med 2025;393:1077–87 (PubMed abstract; full text not reviewed) (accessed 16 November 2026, AEDT).
RACGP newsGP: TGA approves Wegovy weight-loss pill, 4 November 2026 (accessed 16 November 2026, AEDT).